QuickLinks -- Click here to rapidly navigate through this document

Exhibit 10.93

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ISSUED WITHOUT REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY STATE SECURITIES LAWS, AND
MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE TRANSFER IS
EXEMPT FROM REGISTRATION UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS.

THE IMMUNE RESPONSE CORPORATION
8% CONVERTIBLE SECURED PROMISSORY NOTE

$1,000,000   New York, New York
June 24, 2002

        FOR the receipt of $1,000,000 the undersigned, The Immune Response
Corporation, a Delaware corporation (the "Issuer"), hereby unconditionally
promises to pay on the Note Maturity Date (as defined in that certain Note
Purchase Agreement, dated November 9, 2001, by and between the Purchaser, Kevin
Kimberlin Partners, L.P., a Delaware limited partnership, and the Issuer, and as
amended as of February 14, 2002 and further amended as of May 3, 2002 (the "Note
Purchase Agreement")) to the order of Oshkim Limited Partnership, a Delaware
limited partnership (the "Purchaser"), at the office of the Purchaser located at
535 Madison Avenue, 18th Floor, New York, New York 10022, or such other address
designated by the Purchaser, in lawful money of the United States of America and
in immediately available funds, the principal amount of (a) One Million Dollars
($1,000,000) or (b) if less as a result of any voluntary conversion(s) of this
Note in part in accordance with Section 3.4 of the Note Purchase Agreement or in
part into Units as contemplated below, the aggregate unpaid principal amount of
this Note. Subject to Section 3.4 of the Note Purchase Agreement, the Issuer
further agrees to pay interest on the unpaid principal amount outstanding
hereunder from time to time, from the date hereof, in like money, at the rate of
eight (8%) percent per annum, as and at the dates specified in Section 3.3 of
the Note Purchase Agreement.

        This Note is one of the promissory notes referred to in the Note
Purchase Agreement, and is entitled to the benefits thereof, is secured as
provided therein (and as provided in that certain Intellectual Property Security
Agreement, dated November 9, 2001, executed by the Issuer and as amended as of
February 14, 2002) and is subject to conversion as set forth therein.
Notwithstanding the foregoing, this Note (including all accrued interest) is
convertible, at the sole option of the Purchaser, in whole or in part, into
Units (as defined in the Issuer's Definitive Proxy Statement dated May 15, 2002,
the "Proxy") rather than common stock at the Closing Price (as defined in the
Proxy), solely in the event that the Issuer is (i) able to obtain a written
confirmation from The Nasdaq Stock Market that there is an applicable exemption
to do so from all applicable subsections of the National Association of Security
Dealers, Inc. ("NASD") Rule 4350(i) or (ii) able to obtain stockholder approval
as required by NASD Rule 4350(i).

        In the event of any conflict between the Note Purchase Agreement and
this Note, the terms and provisions of the Note Purchase Agreement shall govern.

        Upon the occurrence of (i) any one or more of the Events of Default
specified in the Note Purchase Agreement, or (ii) if Issuer shall default in the
payment of principal on any indebtedness (to any party other that the Purchaser
or KKP) in excess of $200,000 beyond the period of grace, if any, provided in
the instrument or agreement under which such indebtedness was created, all
amounts then remaining unpaid on this Note shall become, or may be declared to
be, immediately due and payable, all as provided in the Note Purchase Agreement.

        Subject to the provisions of the legend above, this Note is freely
transferable, in whole or in part, by the Purchaser, and such transferee shall
have the same rights hereunder as the Purchaser. The

--------------------------------------------------------------------------------

Issuer may not assign or delegate any of its obligations under this Note without
the prior written consent of the Purchaser (or its successor, transferee or
assignee).

        All parties now and hereafter liable with respect to this Note, whether
maker, principal, surety, guarantor, endorser or otherwise, hereby waive
presentment, demand, protest and all other notices of any kind.

        Subject to Section 3.3 of the Note Purchase Agreement, the Issuer agrees
to pay all of the Purchaser's expenses, including reasonable attorneys' costs
and fees, incurred in collecting sums due under this Note.

        This Note shall be subject to prepayment only in accordance with the
terms of the Note Purchase Agreement.

        This Note shall be governed by, and construed and interpreted in
accordance with, the laws of the State of New York.

2

--------------------------------------------------------------------------------

    THE IMMUNE RESPONSE CORPORATION              
 
 
By:
 
 
 
         

--------------------------------------------------------------------------------

        Name:                

--------------------------------------------------------------------------------

        Title:                

--------------------------------------------------------------------------------

3

--------------------------------------------------------------------------------

QuickLinks

Exhibit 10.93 THE SECURITIES REPRESENTED HEREBY HAVE BEEN ISSUED WITHOUT
REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY STATE
SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE ABSENCE OF
AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE
SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT THE TRANSFER IS EXEMPT FROM REGISTRATION UNDER APPLICABLE FEDERAL AND STATE
SECURITIES LAWS.